Peer-reviewed veterinary case report
Probiotic supernatant in lipid carriers fights resistant dog bacteria
By Myo, Nay Zin et al.·Published in Frontiers in veterinary science·2024·Department of Veterinary Microbiology·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Metabolomic profiling and antibacterial efficacy of probiotic-derived cell-free supernatant encapsulated in nanostructured lipid carriers against canine multidrug-resistant bacteria.
- Species:
- dog
Plain-English summary
A study found that a special probiotic treatment made from lactic acid bacteria showed some effectiveness against tough bacteria causing skin infections in dogs. The treatment, which was encapsulated in tiny lipid carriers for better delivery, contained beneficial compounds that helped disrupt the bacteria's cell membranes. Even after being stored for three months, the treatment maintained its ability to inhibit bacterial growth. This suggests that this probiotic-derived therapy could be a helpful option for treating skin infections like dermatitis in dogs caused by multidrug-resistant bacteria.
People also search for: dog skin infection treatment · probiotics for dog dermatitis · antibiotic-resistant bacteria in dogs
Abstract
AIM: This study aimed to investigate the antibacterial efficacy of probiotic-derived cell-free supernatants (CFS) encapsulated within nanostructured lipid carriers (NLCs) against multidrug-resistantand. Additionally, it aimed to identify specific bioactive compounds that contribute to the reported antibacterial properties by characterizing the metabolite substances present in the CFS using a metabolomic analysis technique. METHODS: Eight strains of lactic acid bacteria including(L22F and L25F),(P72N, BF9, BF 14, BYF 20 and BYF 26) and(BF 12) were selected as probiotic candidates. The inhibitory activity of their cell free supernatant (CFS) was tested against clinical strains ofandisolated from skin wounds of dogs and cats. An untargeted metabolomic approach based on liquid chromatography-mass spectrometry (LC-MS) identified potential antibacterial metabolites in the CFS. Cell-Free Supernatants-Nanostructured Lipid Carriers (CFS-NLCs) were developed, and their antibacterial activity and minimum bactericidal concentration (MBC) were analysed. RESULTS: Despite the strong multidrug-resistant nature of the pathogens, CFS displayed a moderate antibacterial activity against most tested strains. The acidic nature of the CFS, combined with bioactive antibacterial metabolites like Kanzonol V and 1-Hexanol, likely contributed to its inhibitory effects against pathogenic bacteria; notably, Kanzonol V was abundant in the CFS of L22F, BF12 and BYF26 (L22F_CFS, BF12_CFS and BYF26_CFS), while 1-Hexanol was particularly enriched in CFS of P72N (P72N_CFS), with both compounds effectively targeting bacterial cell membranes to disrupt cell integrity, leading to bacterial cell death. Other beneficial compounds such as Pyroglutamylleucine, Trigoneoside VIII and 18-Nor-4(19),8,11,13-abietatetraene which are likely to have anti-inflammatory, antimicrobial and antioxidant activities, were also detected in the CFS. The CFS-NLCs maintained their antibacterial activity and 30-60% dilutions of product completely inhibited the growth of pathogen strains even after three-months storage at room temperature. CONCLUSION: These findings suggest that CFS-NLCs could be a promising biotic therapy for treating hospital infections such as canine dermatitis and otitis caused by multidrug-resistantand.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39830167/